Related Experiment Video
Updated: Jul 1, 2025

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
T-cell help in the tumor microenvironment enhances rituximab-mediated NK-cell ADCC
Jyoti Arora1,2, Sabarish Ayyappan1,3, Chaobo Yin1
1Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA.
T cells enhance rituximab therapy by supporting natural killer (NK) cell function. This T-cell help boosts rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) in the tumor microenvironment (TME), improving treatment effectiveness.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Rituximab (RTX) is a monoclonal antibody (mAb) crucial in cancer therapy, primarily acting via antibody-dependent cellular cytotoxicity (ADCC) mediated by natural killer (NK) cells.
- NK cell efficacy is vital for RTX effectiveness, but not all patients respond optimally.
- Previous in vitro studies suggested T cells support NK cell activity.
Purpose of the Study:
- To investigate the role of T-cell help in enhancing RTX-mediated NK-cell ADCC within the tumor microenvironment (TME) in vivo.
- To evaluate the impact of T cells on NK cell viability and function during RTX therapy.
Main Methods:
- Development of a humanized mouse model with controlled T-cell numbers in a lymphoma TME.
- Administration of RTX in the mouse model with and without T cells, and with NK cell depletion.
- Correlative analysis of clinical samples (fine needle aspirates) from indolent lymphoma patients before and after RTX treatment.
Main Results:
- In the mouse model, RTX treatment led to decreased NK cell viability and expression of CD16/CD25 without T cells, but increased these parameters with T cells present.
- RTX therapy efficacy was significantly higher in the presence of T cells and ineffective upon NK cell depletion.
- Clinical data showed a correlation between pre-therapy CD4+ and total T cells in the TME and increased NK cell CD16/CD25 expression post-RTX.
Conclusions:
- T-cell help within the TME is critical for enhancing RTX-mediated NK cell viability and ADCC.
- The presence of T cells significantly improves the effectiveness of RTX therapy.
- Targeting T-cell interactions within the TME could be a strategy to improve RTX efficacy in lymphoma patients.
Related Concept Videos
Tumor Immunotherapy
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
The Tumor Microenvironment
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cells of the Innate Immune Response
Phagocytes
Phagocytes police the peripheral tissues by removing cellular debris and responding to the invasion of foreign substances or pathogens. Many phagocytes attack and remove microorganisms even before lymphocytes detect them. The human body has two general...

